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Abstract
Purpose We explored regret in thyroid cancer patients,
relating to the decision to accept or reject adjuvant
radioactive iodine treatment.
Methods We studied patients with a recent diagnosis of
early stage papillary thyroid carcinoma, in whom treatment
decisions on adjuvant radioactive iodine had been finalized.
Participants completed a Decision Regret Scale question-
naire. We asked the participants to identify who made the
final decision about radioactive iodine treatment. We
explored the relationship between decision regret and a)
degree of patient involvement in decision-making and b)
receipt of radioactive iodine treatment.
Results We included 44 individuals, more than half of
whom received adjuvant radioactive iodine treatment (26/
44). Decision regret was generally low (mean 22.1,
standard deviation [SD] 13.0). Participants reported that
the final treatment decision was made by the following:
patient and doctor (52.3%, 23/44), completely the
patient (27.3%, 12/44), or completely the physician
(20.5%, 9/44). Decision regret significantly differed
according to who made the final decision: the patient
(mean 19.0, SD 11.3), patient and doctor (mean 19.5,
SD 7.4), and the doctor (mean 32.9, SD 20.37) (F=
4.569; degrees of freedom=2, 41; p=0.016). There was no
significant difference in decision regret between patients
who received radioactive iodine and those who did not
(mean difference −2.5; 95% confidence interval −10.6,
5.6; p=0.540).
Conclusion Thyroid cancer patients who reported being
involved in the final treatment decision on adjuvant
radioactive iodine had less regret than those who did not.
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Introduction
Thyroid carcinoma is increasingly being diagnosed [1–5],
especially small primary tumors of papillary thyroid
carcinoma (PTC) discovered at an early stage [3]. PTC is
usually treated with total thyroidectomy, followed in some
cases by adjuvant radioactive iodine (RAI) treatment [6–8].
Decision-making about adjuvant RAI treatment in early
stage PTC is complex and subject to considerable medical
evidence uncertainty. This uncertainty is due to contradic-
tory findings in long-term observational studies and a lack
of high quality evidence from randomized controlled trials
[9]. The impact of the uncertainty of the medical evidence
on patients’ regret of treatment choice is not known.
According to a model of decision-justification theory,
Connolly and Zeelenberg have proposed that regret is
associated with the comparative evaluation of the outcome
of a decision and the feeling of self-blame for having made
a poor choice [10]. From this perspective, regret is regarded
as an aversive emotion, in which people realize or imagine
that their present situation would have been better had they
decided differently in the past [10]. This regret can be
experienced about the decision-making process (“process
regret”) and/or about the outcome of the decision (“out-
comes regret”)[ 10]. Our primary objective in this second-
ary study was to measure outcome regret in thyroid cancer
survivors, relating to the decision to take adjuvant radioac-
tive iodine treatment or not. Furthermore, we explored
process regret by examining the relationship between
patients’ perceived role in radioactive iodine treatment
decision-making and current regret. We also examined
outcome regret, by exploring the relationship between
radioactive iodine treatment status (i.e. whether this
treatment was received or not) and current decision regret.
Methods
Participant recruitment
Participants in this secondary subgroup studywere recruited as
part of a larger study of 50 individuals diagnosed with early
stage PTC, examining the effect of a computerized thyroid
cancer decision aid on medical knowledge [11, 12]. Partic-
ipants were required to have had primary surgical treatment
for thyroid cancer (total thyroidectomy) on September 1,
2007 or later, and they participated in the study between late
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reports for all patients’ thyroidectomy specimens were
reviewed. Participants were required to have a primary PTC
tumor 4 cm or smaller in diameter with no known positive
lymph nodes and no known distant metastases, with no
venous or lymphatic invasion, and no tall cell features, noted
on surgical pathology examination [11, 12]. We included only
English-speaking individuals aged 18 years or older who had
a prior thyroidectomy (completed in one or two stages), who
were able to use a computer, in this study [11, 12].
Individuals with a single intra-thyroidal PTC measuring less
than 1 cm in diameter or those who had undergone only a
hemi-thyroidectomy (with no completion thyroidectomy)
were not eligible [11, 12] since they are typically not offered
RAI treatment. The measurement of decision regret was
restricted to 44 participants in whom decision-making about
adjuvant radioactive iodine was completed and who had
either received radioactive iodine treatment or not received it
(with no plans to receive it). These 44 participants had no
exposure to our decision aid at the time of RAI treatment
decision-making or prior to completing the decision regret
questionnaire. All of these individuals received usual
counseling and care from their treating physicians, relating
to decision-making on radioactive iodine treatment, prior to
participation in the study. The study was approved by the
University Health Network Research Ethics Board, and all
participants provided informed consent.
Study procedure and questionnaires
At baseline (i.e. prior to exposure to any decision aid
intervention), participants were asked to complete written
questionnaires on their medical history and radioactive iodine
treatment decision-making. We asked the participants to
identify who made the final decision for the patient to take
or not take adjuvant RAI treatment, and they were offered the
following options (choose one): completely my choice (with
or without input from my family or friends), completely my
doctor’s choice, my doctor and I made the decision together
(with or without input from my family or friends), someone
else’s choice (other than me and my doctor), or the final
decision on RAI treatment has not yet been made (still
thinkingabout it).Participantswhose RAI treatmentdecision-
making was completed were also asked to complete a
validated decision regret questionnaire [13], specifically
considering the decision to accept or reject adjuvant RAI
treatment. The decision regret questionnaire is scored on a
scale of 0 to 100, with 100 representing maximal regret [13].
Analyses
The sample size of 44 respondents was primarily based on
feasibility considerations, since the study was designed for
exploratory or hypothesis-generation purposes. Descriptive
data were presented as mean and standard deviation (SD) for
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data. Respective exploratory analyses using analysis of
variance (ANOVA) and an independent samples Student’s t-
test were performed, to compare decision regret according to
perceived RAI treatment final decision maker (collapsed to
three levels, i.e. the patient, shared decision between patient
and doctor, and the doctor) and RAI treatment status (i.e.
received vs. not received). Although we could not ascertain
the exact date when decision-making about RAI treatment
was finalized, such decisions generally follow completion of
thyroidectomy. Therefore, we used the year of completion of
thyroidectomy (years 2007, 2008, and 2009) as a reasonable
surrogate for the time when RAI decision-making was
performed. An exploratory post-hoc Pearson correlation
statistic was calculated, examining the relationship between
the year when thyroidectomy was completed and current
decision regret, to determine whether regret tended to vary
over time. The criterion for statistical significance was set at
alpha=0.05. We did not adjust the overall level of
significance for multiple testing as the analyses were
primarily exploratory. Quantitative statistical analyses were
performed using PASW Statistics 18.0 (IBM, Chicago, IL).
Results
Study sample
The study sample was comprised of 37 women and seven
men who had been diagnosed with PTC at thyroidectomy.
The demographic characteristics of the study population are
shown in Table 1. The study population represented a wide
age range, and the majority had an education level higher
than high school (90.9%). More than half of the study
population (26/44) had received adjuvant radioactive iodine
treatment, and the rest had not received it (with no plans to
receive it). More than half of the participants perceived that
the final decision to accept or reject RAI treatment had been
shared between themselves and their physician (23/44)
(Table 1). Fewer patients perceived the decision to have
been completely theirs (27.3%, 12/44) or completely their
treating physician’s (20.5%, 9/44), respectively.
Regret related to radioactive iodine treatment
decision-making
In general, participants had a relatively low level of
decision regret related to RAI treatment choice (mean value
of 22.1, SD 13.0). However, in an exploratory analysis,
decision regret was found to significantly differ according
to who made the final treatment decision: the patient (mean
19.0, SD 11.3, n=12 individuals), shared between the
patient and doctor (mean 19.5, SD 7.4, n=23), or the doctor
(mean 32.9, SD 20.4, n=9)(F=4.569; degrees of freedom=
2, 41; p=0.016). There was no significant difference in
decision regret between the 26 patients who received RAI
treatment (mean 21.1, SD 12.7) and the 18 who did not
receive this treatment (mean 23.6, SD 13.6) (mean
difference −2.5; 95% confidence interval −10.6, 5.6; p=
0.540). We found no significant correlation between the
Table 1 Demographic charac-
teristics of participants
aYear thyroidectomy completed
refers to the year when total
thyroidectomy was performed
(if performed in one stage) or, in
the case of a two-stage thyroid-
ectomy, to the year of the
second procedure
Characteristic Number (%)
Age (years) 18 to 30 5/44 (11.4)
31 to 40 9/44 (20.5)
41 to 50 17/44 (38.6)
51 to 60 9/44 (20.5)
61 or older 4/44 (9.1)
Female gender 37/44 (84.1)
Received adjuvant radioactive iodine treatment 26/44 (59.1)
Year thyroidectomy completed
a 2007 19/44 (43.2)
2008 17/44 (38.6)
2009 8/44 (18.2)
Highest level of education High school 4/44 (9.1)
College or university 26/44 (59.1)
Postgraduate or medicine 14/44 (31.8), including
one physician
Who was perceived as making the final decision
on adjuvant radioactive iodine treatment
Completely patient’s choice 12/44 (27.3)
Completely doctor’s choice 9/44 (20.5)
Doctor and patient made
decision together
23/44 (52.3)
Someone else 0/44 (0)
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regret (r=0.112, p=0.469).
Discussion
In this study, early stage PTC survivors had a relatively low
level of decision regret relating to taking adjuvant RAI
treatment or not. However, individuals who perceived that
their physician made the final treatment decision on RAI
treatment without their involvement reported significantly
more decision regret than those who felt involved in final
treatment decision-making (i.e. making the decision them-
selves or sharing decision-making with their physician).
Our findings are similar to those of Brehaut et al., who
reported, in a study of decision-making in women regarding
hormone replacement therapy, that the level of regret was
significantly greater in women who indicated that their
physician was the main decision-maker, compared to those
who felt they were the main decision-maker or that the
decision-making was shared between themselves and their
physicians [13]. We did not find any relationship between
the receipt of RAI treatment or not and the level of decision
regret. It has been postulated that feeling regret is related to
perception of lost opportunities [14, 15], so it is possible
that these individuals minimized the perception of such
losses. In that regard, Lin reported that prostate cancer
survivors’ decision regret relating to radical prostatectomy
was associated with experiencing treatment side effects
[16]. Furthermore, prostate cancer survivors who felt they
understood the treatment and complications had signifi-
cantly less regret at follow-up [16]. We did not collect data
on thyroid cancer treatment side effects or patients’
perceptions of feeling well-informed about treatment choice
at the time of decision-making. However, we did not find
any relationship between time since completion of thyroid-
ectomy (as a surrogate of timing of RAI treatment decision-
making) and subsequent regret, although timing of decision
regret measurement was limited to within a few years after
completion of thyroidectomy. Lin also did not find a
significant relationship between time since surgical treat-
ment of prostate cancer and decision regret, up to 46 months
after radical prostatectomy [16].
In the recent Salsburg Statement on Shared Decision
Making, international experts called on clinicians to
recognize an ethical imperative to share important
decision-making with patients, stimulate a two-way flow
of information between clinicians and patients, provide
accurate information about options and uncertainties, and
tailor information to individual patients’ needs [17].
Although patient preferences for participation in healthcare
decision-making are variable [18], data from our study as
well as others [13] suggest that involving patients in
decision-making in clinical practice may be associated with
reduced decision regret among patients.
Our study is subject to a number of limitations,
including the following: a small sample size, a cross-
sectional design for analysis of decision regret with a
lack of prospective follow-up data, limited time duration
from decision-making to the measurement of decision
regret, the reporting of exploratory secondary analyses,
and the reliance on patients’ perceptions of RAI
treatment decision-making process with no objective
information on patient–physician interactions (such as
video or audio recordings of the meetings). Our study
may have also been subject to some recruitment bias, as
participants were recruited as part of a larger study to
evaluate a computerized decision aid and therefore
could have particularly valued participation in medical
decision-making. Also, most individuals in this study
were English speaking and had higher education, so the
results may not be generalizable to non-English speak-
ing or less educated populations. Finally, we did not
collect any data on disease recurrence status or possible
thyroid cancer treatment side effects.
In conclusion, the findings from this exploratory,
hypothesis-generating study suggest that a lack of
patient involvement in healthcare decision-making may
be associated with increased decision regret. This
hypothesis needs to be validated in a larger prospective
study, formally examining decision regret in patients at
multiple points over time, ideally with direct examina-
tion of patient–physician interactions at the time of
decision-making. Further research is also needed to
better understand the different ways in which patients
may be involved in medical decision-making and its
potential impact on future emotional health and well-
being. Such research may benefit patients and clinicians
in all medical and surgical fields, who may be involved
in healthcare decision-making.
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